ClearPoint Neuro, Inc. filings document the company's medical-device and therapy-enabling business, including operating results for its brain and spine navigation platforms, CNS drug-delivery services, and neurocritical-care portfolio after the completed IRRAS Holdings acquisition. Form 8-K reports furnish quarterly and annual results, Regulation FD investor presentations, acquisition-related financial statements, pro forma combined financial information, and material-event disclosures.
Proxy materials cover governance matters, director voting, executive compensation, pay-versus-performance data, and equity-award disclosures. The filing record also includes material agreements, capital-structure disclosure, shareholder voting matters, and clinical or regulatory disclosures tied to the company's regulated neurosurgical products and partnered biologics programs.
BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of common stock of ClearPoint Neuro, Inc.. BlackRock reports beneficial ownership of 2,118,912 shares of common stock, representing 7.1% of the class.
BlackRock has sole voting power over 2,087,782 shares and sole dispositive power over 2,118,912 shares, with no shared voting or dispositive power. Various underlying clients have economic rights to dividends and sale proceeds, but no single client holds more than five percent of the outstanding common shares.
FLETCHER R JOHN reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro director R. John Fletcher received 662 shares of Common Stock as compensation. The shares were issued under the company’s incentive and non-employee director compensation plans at a value of $17.84 per share, matching the June 30, 2026 closing price. After this grant, Fletcher directly holds 131,011 shares.
Richards Timothy T. reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro director Timothy T. Richards received 222 shares of Common Stock as compensation. The shares were granted on June 30, 2026 under the company’s Seventh Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed under the Non-Employee Director Compensation Plan.
The shares were valued at a price of $17.84 per share, matching the closing price of ClearPoint Neuro’s stock on June 30, 2026. Following this award, Richards directly holds 87,544 shares of ClearPoint Neuro common stock, indicating this was a routine, small incremental grant rather than a large new position.
ClearPoint Neuro, Inc. Chief Business Officer L. Jeremy Stigall acquired 1,781 shares of common stock through the company’s Employee Stock Purchase Plan. These shares were purchased for $11.93 per share for the ESPP period from January 1, 2026 through June 30, 2026.
After this ESPP acquisition, Stigall directly holds a total of 110,263 shares of ClearPoint Neuro common stock. Under the ESPP terms, the purchase price was 85% of the fair market value on the first or last day of the purchase period, whichever was lower.
ClearPoint Neuro Chief Financial Officer Danilo D'Alessandro acquired 1,085 shares of common stock through the company’s Employee Stock Purchase Plan. The shares relate to the ESPP purchase period from January 1, 2026 through June 30, 2026 and were bought at $11.93 per share. After this routine compensation-related acquisition, he directly holds 103,769 shares of ClearPoint Neuro common stock.
ClearPoint Neuro, Inc. CEO and President Joseph Burnett reported routine insider activity involving company common stock. He acquired 1,361 shares of common stock on June 30, 2026 as a grant/award under the company’s Employee Stock Purchase Plan (ESPP) at $11.93 per share. The ESPP purchase covered the period from January 1, 2026 through June 30, 2026, with shares bought at 85% of the lower of the fair market value on the first or last day of that period. Following this ESPP acquisition, Burnett directly owns 118,203 shares of ClearPoint Neuro common stock and indirectly has 191,388 shares held through the Joseph M. Burnett Trust dated October 20, 2022, where he serves as trustee.
ClearPoint Neuro, Inc. director and CEO Joseph Burnett reported an option exercise and related share sale in Common Stock. He exercised stock options to acquire 20,000 shares at $2.50 per share and sold 20,000 shares in an open-market transaction at a weighted average price of $19.38 per share.
Following these transactions, he holds 116,842 shares directly and 191,388 shares indirectly through the Joseph M. Burnett Trust. The filing notes the exercise and sale were made under a pre-arranged Rule 10b5-1 trading plan adopted on June 11, 2025.
CLPT notice of proposed sale: a planned sale of 20,000 shares of Common Stock via exercise of stock options for cash on 06/29/2026. The filing also records prior 10b5-1 transactions on 06/17/2026 totaling 61,843 shares (60,000 and 1,843) with disclosed proceeds of $1,067,204.00 and $33,060.84, respectively.
ClearPoint Neuro, Inc. CEO and President Joseph Burnett reported an exercise-and-sell transaction in company stock. He exercised stock options for 60,000 shares of common stock at $2.50 per share and sold 60,000 shares held directly at a weighted average price of $17.79 per share. In a separate indirect transaction, the Joseph M. Burnett Trust dated 10/20/2022, for which he serves as trustee, sold 1,843 shares at a weighted average price of $17.94 per share. Following these transactions, Burnett held 116,842 shares directly and 191,388 shares indirectly through the trust, and the option award referenced in the filing covered 270,000 shares after the exercise. The filing notes that the option exercise and related sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on June 11, 2025.